FTSE MIB
34.249,77 +310,02 (+0,91%) Dow Jones
38.239,66 +153,86 (+0,40%) Nasdaq
15.927,90 +316,14 (+2,03%) Nikkei 225
37.934,76 +306,28 (+0,81%) Petrolio
83,66 +0,09 (+0,11%) Bitcoin EUR
59.750,10 +772,02 (+1,31%)
CSL Limited (CSL.AX)
| Chiusura precedente | 278,45 |
| Aperto | 275,10 |
| Denaro | 293,53 x 13700 |
| Lettera | 273,61 x 21700 |
| Min-Max giorno | 272,37 - 275,24 |
| Intervallo di 52 settimane | 228,65 - 312,99 |
| Volume | |
| Media Volume | 724.103 |
| Capitalizzazione | 132,073B |
| Beta (5 anni mensile) | 0,29 |
| Rapporto PE (ttm) | 34,86 |
| EPS (ttm) | 7,84 |
| Prossima data utili | 13 feb 2024 |
| Rendimento e dividendo (futuro) | 3,81 (1,39%) |
| Data ex dividendo | 11 mar 2024 |
| Stima target 1A | 302,44 |
GlobeNewswireuniQure announces achievement of $100 million milestone related to hemophilia B gene therapy
Milestone payment triggered by first commercial sale of HEMGENIX® in U.S. by CSL BehringLEXINGTON, Mass. and AMSTERDAM, June 20, 2023 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, announced the achievement of a $100 million milestone associated with the first commercial sale of HEMGENIX® in the United States by its partner, global biotechnology leader CSL (ASX: CSL). HEMGENIX® (etranacoge
GlobeNewswireKapruvia® (difelikefalin) recommended by England’s NICE for the treatment of adults with moderate-to-severe CKD-associated pruritus
Recommendation will enable eligible patients in England, Wales and Northern Ireland to access the first licensed treatment for moderate-to-severe chronic kidney disease (CKD)-associated pruritus in adult patients on haemodialysisST. GALLEN, Switzerland and STAMFORD, Conn., May 18, 2023 (GLOBE NEWSWIRE) -- Vifor Fresenius Medical Care Renal Pharma (VFMCRP) and Cara Therapeutics, Inc. (Nasdaq: CARA) today announced that England’s National Institute for Health and Care Excellence (NICE) has recomme
